dc.contributor.author |
Rasmussen, TA |
|
dc.contributor.author |
Ahuja, SK |
|
dc.contributor.author |
Kuwanda, L |
|
dc.contributor.author |
Vjecha, MJ |
|
dc.contributor.author |
Hudson, F |
|
dc.contributor.author |
Lal, L |
|
dc.contributor.author |
Rhodes, A |
|
dc.contributor.author |
Chang, J |
|
dc.contributor.author |
Palmer, S |
|
dc.contributor.author |
Auberson-Munderi, P |
|
dc.contributor.author |
Mugerwa, H |
|
dc.contributor.author |
Wood, R |
|
dc.contributor.author |
Badal-Faesen, S |
|
dc.contributor.author |
Pillay, S |
|
dc.contributor.author |
Mngqibisa, R |
|
dc.contributor.author |
LaRosa, A |
|
dc.contributor.author |
Hildago, J |
|
dc.contributor.author |
Petoumenos, K |
|
dc.contributor.author |
Chiu, C |
|
dc.contributor.author |
Lutaakome, J |
|
dc.contributor.author |
Kitonsa, J |
|
dc.contributor.author |
Kabaswaga, E |
|
dc.contributor.author |
Pala, P |
|
dc.contributor.author |
Ganoza, Carmela |
|
dc.contributor.author |
Fisher, K |
|
dc.contributor.author |
Chang, C |
|
dc.contributor.author |
Lewin, SR |
|
dc.contributor.author |
Wright, EJ |
|
dc.date.accessioned |
2022-06-25T20:36:43Z |
|
dc.date.available |
2022-06-25T20:36:43Z |
|
dc.date.issued |
2022 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12866/11892 |
|
dc.description.abstract |
Background: Identifying factors that determine the frequency of latently infected CD4+ T cells on antiretroviral therapy (ART) may inform strategies for human immunodeficiency virus (HIV) cure. We investigated the role of CD4+ count at ART initiation for HIV persistence on ART. Methods: Among participants of the Strategic Timing of Antiretroviral Treatment Study, we enrolled people with HIV (PWH) who initiated ART with CD4+ T-cell counts of 500–599, 600–799, or ≥ 800 cells/mm3. After 36–44 months on ART, the levels of total HIV-DNA, cell-associated unspliced HIV-RNA (CA-US HIV-RNA), and two-long terminal repeat HIV-DNA in CD4+ T cells were quantified and plasma HIV-RNA was measured by single-copy assay. We measured T-cell expression of Human Leucocyte Antigen-DR Isotype (HLA-DR), programmed death-1, and phosphorylated signal transducer and activator of transcription-5 (pSTAT5). Virological and immunological measures were compared across CD4+ strata. Results: We enrolled 146 PWH, 36 in the 500–599, 60 in the 600–799, and 50 in the ≥ 800 CD4 strata. After 36–44 months of ART, total HIV-DNA, plasma HIV-RNA, and HLA-DR expression were significantly lower in PWH with CD4+ T-cell count ≥ 800 cells/mm3 at ART initiation compared with 600–799 or 500–599 cells/mm3. The median level of HIV-DNA after 36–44 months of ART was lower by 75% in participants initiating ART with ≥ 800 vs 500–599 cells/mm3 (median [interquartile range]: 16.3 [7.0–117.6] vs 68.4 [13.7–213.1] copies/million cells, respectively). Higher pSTAT5 expression significantly correlated with lower levels of HIV-DNA and CA-US HIV-RNA. Virological measures were significantly lower in females. Conclusions: Initiating ART with a CD4+ count ≥ 800 cells/mm3 compared with 600–799 or 500–599 cells/mm3 was associated with achieving a substantially smaller HIV reservoir on ART. |
en_US |
dc.language.iso |
eng |
|
dc.publisher |
Oxford University Press |
|
dc.relation.ispartofseries |
Clinical Infectious Diseases |
|
dc.rights |
info:eu-repo/semantics/restrictedAccess |
|
dc.rights.uri |
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es |
|
dc.subject |
HIV |
en_US |
dc.subject |
HIV reservoir |
en_US |
dc.subject |
antiretroviral therapy |
en_US |
dc.subject |
HIV cure |
en_US |
dc.title |
Antiretroviral Initiation at >= 800 CD4+Cells/mm(3) Associated With Lower Human Immunodeficiency Virus Reservoir Size |
en_US |
dc.type |
info:eu-repo/semantics/article |
|
dc.identifier.doi |
https://doi.org/10.1093/cid/ciac249 |
|
dc.subject.ocde |
https://purl.org/pe-repo/ocde/ford#3.03.08 |
|
dc.relation.issn |
1537-6591 |
|